Weekly roundup: More questions for Novartis in Zolgensma sca...

It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.

3rd Annual Dermatology Drug Development Summit

Industry meeting on advancing derm drug development

Fallout over Zolgensma data scandal continues for Novartis

US senators blast Novartis for Zolgensma data falsification

US politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data used in the approval of its $2.1 million spinal muscular atrophy (SMA) gene therapy Zolge

Shield Therapeutics soars on FDA approval of iron deficiency...

Shares in Shield Therapeutics were soaring this morning after the FDA granted a broader than expected label for its iron deficiency drug.

Allergan pulls breast implants after link to rare cancer